Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 8/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18258640 | 1.00 | KMT2A (0.61) | KMT2AGAAKDM4ECASP1CASP7 | |
| SCHEMBL18974288 | 1.00 | KMT2A (0.61) | KMT2AGAAKDM4ECASP1CASP7 | |
| SCHEMBL4803383 | 0.81 | CES1 (0.53) | KMT2AGAACES1TTRALDH1A1 | |
| SCHEMBL18281472 | 0.80 | CES1 (0.57) | KMT2AGAACES1TTRALDH1A1 | |
| SCHEMBL29472125 | 0.80 | LMNA (0.71) | KMT2AGAAKDM4ECASP1CASP7 | |
| SCHEMBL4199767 | 0.80 | CES1 (0.57) | KMT2AGAAKDM4ECES1LMNA | |
| SCHEMBL7399848 | 0.80 | LMNA (0.71) | KMT2AGAAKDM4ECASP1CASP7 | |
| SCHEMBL478339 | 0.80 | LMNA (0.71) | KMT2AGAAKDM4ECASP1CASP7 | |
| SCHEMBL125972 | 0.80 | LMNA (0.71) | KMT2AGAAKDM4ECASP1CASP7 | |
| SCHEMBL18954547 | 0.80 | ALDH1A1 (0.49) | KMT2AKDM4ECASP1CASP7CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3098217-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | UNIV TOKYO SCIENCE FOUND (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-9796640-B2 | Method for producing optically active carboxylic acid ester | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2017-10-24 | — | — | US | disclosed |
| WO-2017099695-A1 | N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | ISTANBUL UNIVERSITESI REKTORLUGU (TR) | 2017-06-15 | — | — | WO | disclosed |
| US-20170008820-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2017-01-12 | — | — | US | disclosed |
| EP-3098217-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | Tokyo University of Science Foundation (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2428515-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| EP-2073806-B1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-15 | — | — | EP | disclosed |
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20110251224-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-7935721-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-05-03 | — | — | US | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008820-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | ADH1A, ALDH1A2, ADH1C | KMT2A 2579/4885GAA 1175/4885KDM4E 3163/4885 |
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | KMT2A 1139/4885GAA 4380/4885KDM4E 3817/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | KMT2A 2666/4885GAA 4464/4885KDM4E 3433/4885 |
| US-20110251224-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | KMT2A 2666/4885GAA 4464/4885KDM4E 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.